6660 (6660) Fair Value & Analysis
Healthcare · Market cap HK$2.1B
Fair value as of: Jul 2, 2026
From 3 valuation models · updated today
Share price −22.8% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$1.65 – HK$5.76 · fair‑value band HK$1.92 – HK$2.41 · the HK$1.79 price screens below the HK$2.11 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
6660 (6660) currently trades at HK$1.79, while our model-based Fair Value estimate is HK$2.11 — implying the stock looks roughly 17.9% undervalued today. We read business quality at 28/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, 6660 generated revenue of HK$1.2B at a net margin of -58.0%. Revenue declined 12.9% year over year. It earns a return on equity of -22.7%. Net debt stands at HK$1.4B. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
6660 reported revenue of HK$1.2B in FY2025 versus HK$1.6B in FY2021, a compound −7.2%/yr. Reported net income was −HK$675M in FY2025.
Is 6660 fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 6660 (6660) undervalued?
What is the fair value of 6660?
What is the quality score of 6660?
What is the revenue of 6660 (6660)?
What is the net profit margin of 6660?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.